Altnagelvin Area Hospital is the main hospital for the North West of Northern Ireland. It is located in Waterside, Derry. It provides services to the city of Derry and County Londonderry, but also some specialist and acute services for parts of neighbouring County Donegal, County Tyrone, County Antrim and County Fermanagh. It is managed by the Western Health and Social Care Trust.
Introduction: Patients undergoing total knee arthroplasty under neuraxial anaesthesia remain awake within a stressful operative environment. Music listening is a low-cost, non-pharmacological intervention that may reduce anxiety and pain. Methods: We searched PubMed, MEDLINE, Embase and Cochrane Central Register of Controlled Trials from inception to April 2026. Standardised mean differences were pooled using random-effects models; risk of bias was assessed with Cochrane Risk of Bias 2. Results: Eight randomised controlled trials (440 participants) were included. Music listening significantly reduced postoperative anxiety (standardised mean difference = −0.95; 95% confidence intervals: −1.34 to −0.55) and postoperative pain at 24 h (standardised mean difference = −0.81; 95% confidence interval: −1.23 to −0.39) and was associated with reduced opioid consumption, lower intraoperative sedation requirements, fewer conversions from neuraxial to general anaesthesia and higher patient satisfaction. Subgroup analysis suggests that a proportion of the benefit may be attributable to noise isolation from headphones alone rather than to music. Conclusion: Low-certainty evidence suggests music may be an optional, low-cost adjunct within enhanced recovery after surgery pathways for total knee arthroplasty. Further research is needed to refine optimal intervention protocols and validate benefits in larger multicentre trials.
Ischaemic stroke does not occur at random hours. Onset clusters in the morning, and several physiological correlates of that pattern are well described: an endogenous circadian peak in circulating plasminogen activator inhibitor-1, platelets that aggregate more readily in the hours after rising, and the morning surge in blood pressure. What remains unsettled is whether the hour of onset also influences how quickly brain tissue is lost and how well it responds to treatment. This critical narrative review draws together molecular, experimental and clinical evidence and organises it as a Three-Clock Model: a trigger clock that sets when vessels occlude, a tissue clock that governs the pace of infarct growth, and a treatment clock that modulates the response to reperfusion and to adjunctive or neuroprotective therapy. Human cohorts have reported larger ischaemic cores and faster infarct growth after night-time onset or during night-time interhospital transfer, the latter measured directly with serial diffusion-weighted imaging, and time-of-day differences in thrombectomy outcome, but these associations are vulnerable to confounding by uncertain onset times, out-of-hours care and the gap between clock time and internal circadian phase. In rodents, three neuroprotective strategies reduced infarction when given during the animals’ inactive phase but not during the active phase, a mismatch that may have contributed to failed translation; other experiments disagree about which phase is more damaging. Large pragmatic trials of bedtime antihypertensive dosing have been neutral. We propose a ten-item CHRONO-STROKE minimum reporting dataset, which is author-proposed and unvalidated and intended to supplement existing consensus data elements, a clock-time-stratified design for trials of adjunctive therapy, and five testable predictions, as a means of establishing whether circadian biology deserves a place in acute stroke decision-making.
Introduction Medial patellofemoral ligament (MPFL) reconstruction is a useful technique for managing patellar instability. Various grafts choices and outcomes are reported, however, no randomised control trial directly comparing autograft to synthetic grafts exist. This paper is the result of a previously published clinical trial protocol directly comparing graft choices. Methods An ISRCTN registered, non-inferiority, prospective randomised-control trial was conducted. Full trial protocol was previously published. Patient demographics, radiological parameters and clinical outcomes were collated. A sample size was estimated based on previously published studies. A 1:1 recruitment with block randomisation was performed. Validated knee outcome scores are reported. Data was blinded for all analyses based on an intention to treat design. A p < 0.05 was considered statistically significant. Results A total of 20 patients in each arm were prospectively followed for a minimum of 2 years post surgery. Follow up retained an adequately powered study based on the protocol. Mean age of 19.1 ± 3.6 years. Tegner, Lysholm, Kujala, International Knee Documentation Committee (IKDC) and Banff Patellar Instability Index (BPII) all improved post operatively, mainly at 1 year. Recovery trajectory showed 2/3 improve at 1 year, and further improvement occurs in 1/3 of patients out to 2 years irrespective of graft choice. Outcome scores were not significantly different between graft groups at any time points. Functional strength assessment showed significantly higher strength with autologous reconstruction at 1 and 2 years post op. Conclusion No significant difference in outcomes were observed between autologous hamstring and synthetic reconstruction of the MPFL. Further large scale Randomised Control Trials (RCTs) are required comparing autograft and synthetic alternatives.
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely used for type 2 diabetes and obesity management, yet their effects on thyroid function tests remain inadequately characterized. Preclinical rodent studies demonstrating C-cell hyperplasia have raised safety concerns, while clinical evidence regarding thyroid hormone dynamics is sparse and inconsistent. This systematic review aimed to synthesize available evidence on the effects of GLP-1 receptor agonists on thyroid function tests, explicitly acknowledging that direct evidence is limited and that characterizing this evidence gap is a primary objective. A comprehensive search of PubMed, Scopus, Web of Science, and ClinicalTrials.gov was conducted for studies published between January 2021 and December 2025. Eligible studies included randomized controlled trials and observational studies evaluating thyroid function parameters in adult patients receiving GLP-1 receptor agonists. Risk of bias was assessed using the Cochrane Risk of Bias 2 tool for randomized trials and the Risk Of Bias In Non-randomized Studies of Interventions tool for observational studies. A narrative synthesis was performed due to substantial methodological heterogeneity precluding meta-analysis. Six studies encompassing 900,225 participants met the inclusion criteria, including three randomized controlled trials, two retrospective cohort studies, and one combined Mendelian randomization and cohort study. Only one study directly assessed thyroid function tests, reporting a mild decrease in free thyroxine and slight thyroid nodule progression after 12 months of therapy, though Mendelian randomization analysis revealed no significant causal effect. The remaining five studies did not systematically evaluate thyroid function parameters, focusing instead on thyroid malignancy outcomes or weight loss efficacy. The large-scale cohort studies demonstrated no increased risk of thyroid tumors or thyroid cancer with GLP-1 receptor agonist use. Risk of bias was low for two observational studies and moderate for one due to potential residual confounding, while two randomized trials demonstrated low risk of bias and one raised some concerns regarding outcome measurement. This systematic review aims to critically evaluate the available evidence - and, more explicitly, to characterize the substantial evidence gap - concerning the effects of GLP-1 receptor agonists on thyroid function tests. While only one of six included studies directly addressed this outcome, and available data suggest no increased thyroid malignancy risk, definitive conclusions regarding functional thyroid effects cannot be drawn due to the absence of systematic thyroid function assessments in most included studies, particularly the major randomized controlled trials. Future research should incorporate systematic thyroid hormone monitoring to clarify the clinical significance of GLP-1 receptor agonist therapy on thyroid axis regulation.